Multiple Myeloma
Advertisement
The Patient Navigation Center at the Multiple Myeloma Research Foundation addresses barriers to care and supports patients.
Talquetamab showed "robust and durable responses" for patients with relapsed/refractory multiple myeloma.
Oncology nurses may be the first to identify the classic triad of hyperviscosity syndrome symptoms.
Almost all patients with multiple myeloma at some point will develop bone disease—the “B” in CRAB.
Lisa Hwa, APRN, CNP, DNP, MS, said the comprehensive fellowships will help prepare APPs working in complex specialties.
Understanding critical symptoms in the “CRAB” acronym can enable oncology nurses to educate patients and caregivers.
Up to 50% of patients have renal insufficiency at the time of multiple myeloma diagnosis.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses her experiences and shares resources.
Amy Pierre, RN, BSN, ANP-BC, shares her insights on disparities in myeloma and the steps APPs can take to address them.
New research highlights the need for “early and equitable” integration of palliative care for patients with myeloma.
Blood Cancer Awareness Month represents a critical opportunity to provide education on early signs and symptoms.
Amy Pierre, RN, BSN, ANP-BC, shares what the annual observance means to her and the field as a whole.
Hear about an NP's journey into hematologic oncology and how she has seen the treatment landscape evolve.
A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission.
Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care.
Learn about the diverse unmet needs and potential solutions related to the experiences of patients and caregivers.
A subgroup analysis of CARTITUDE-4 evaluated ciltacabtagene autoleucel in functionally high-risk multiple myeloma.
The survey results will be used to formulate recommendations to improve patient involvement in decision making.
Nurses may be able to play a role in aligning views between patients and hematologists on prognosis and goals of care.
The approval is for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for ASCT.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.